StocksP › PCH

PotlatchDeltic Corporation (PCH) — Earnings Call X-Ray

Our AI read all 38 of PCH's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2025 · sign up to see
Previous Call Grade
A
Q4 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
38
2016–2025
Avg Candor
7.8/9
evasion 1.7/9
High CandorSkeptic ReassuredClean CallVolume Step-UpEarly Product, Fast GrowthUnderused Fixed CostsRaising PricesMargins Expanding

Call-by-call analysis

🔒 Q1 2025 earnings call 2025-04-29 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2025 call grade is ready
The full 37-point AI read of PCH's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

A Q4 2024 earnings call 2025-01-28 move ±9.4%

Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: mixedMargins: expandingPricing: raisingCapex: decreasing 7 analysts · 19 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 8/9
Specificity 8/9
Evasion 1/9
Confidence 7/9
Uncertainty 5/9
Promotion 3/9
Stress 1/9
Complexity 6/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q3 2024 earnings call 2024-10-29 move ±10%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: mixedMargins: contractingPricing: raisingCapex: decreasing 6 analysts · 16 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 8/9
Specificity 9/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C Q2 2024 earnings call 2024-07-30 move ±9.5%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: contractingPricing: under pressureCapex: decreasing 6 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 4/9
Confidence 6/9
Uncertainty 5/9
Promotion 5/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

D Q1 2024 earnings call 2024-04-30 move ±8.5%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: contractingBacklog: shrinkingPricing: under pressureCapex: increasing 6 analysts · 19 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Volume step-up ahead✓ Early product, fast growthDirection beats results
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 6/9
Uncertainty 6/9
Promotion 3/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B Q4 2023 earnings call 2024-01-30 move ±7.7%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: mixedMargins: contractingPricing: under pressureCapex: increasing 7 analysts · 21 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growthDirection beats results
Candor 8/9
Specificity 9/9
Evasion 2/9
Confidence 6/9
Uncertainty 4/9
Promotion 5/9
Stress 1/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C+ Q3 2023 earnings call 2023-10-31 move ±8%

Management lowered guidance against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: mixedMargins: contractingPricing: under pressureCapex: flat 7 analysts · 20 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsDirection beats results
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 6/9
Uncertainty 6/9
Promotion 4/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

A Q2 2023 earnings call 2023-08-01 move ±8.2%

Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: mixedMargins: expandingPricing: raisingCapex: increasing 8 analysts · 23 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growthDirection beats results
Candor 8/9
Specificity 9/9
Evasion 1/9
Confidence 7/9
Uncertainty 3/9
Promotion 5/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q1 2023 2023-04-25 A maintainedmixedcontracting 8/9 1/9
Q4 2022 2023-01-31 C+ loweredmixedcontracting 8/9 2/9
Q3 2022 2022-10-25 B+ maintainedmixedcontracting 8/9 2/9
Q2 2022 2022-07-26 B+ loweredslowingcontracting 8/9 1/9
Q1 2022 2022-04-26 A raisedstableexpanding 8/9 1/9
Q4 2021 2022-02-01 A raisedacceleratingexpanding 8/9 2/9
Q3 2021 2021-10-26 B+ maintainedstablecontracting 8/9 1/9
Q2 2021 2021-07-27 C+ loweredmixedcontracting 8/9 2/9
Q1 2021 2021-04-27 A raisedacceleratingexpanding 7/9 2/9
Q4 2020 2021-02-02 A raisedacceleratingexpanding 8/9 1/9
Q3 2020 2020-10-27 A raisedacceleratingexpanding 8/9 1/9
Q2 2020 2020-07-28 A raisedacceleratingexpanding 8/9 2/9
Q1 2020 2020-04-28 C+ loweredmixedcontracting 8/9 2/9
Q4 2019 2020-02-04 B+ maintainedacceleratingunclear 8/9 2/9
Q3 2019 2019-10-29 C+ loweredmixedcontracting 8/9 1/9
Q2 2019 2019-07-30 B+ maintainedmixedcontracting 8/9 1/9
Q1 2019 2019-04-30 A maintainedmixedstable 8/9 2/9
Q4 2018 2019-02-05 B+ loweredstablecontracting 8/9 2/9
Q3 2018 2018-10-29 C+ loweredstablecontracting 7/9 2/9
Q2 2018 2018-07-31 A raisedstableexpanding 8/9 1/9
Q1 2018 2018-05-04 A raisedacceleratingexpanding 7/9 2/9
Q4 2017 2018-01-30 A raisedacceleratingexpanding 8/9 2/9
Q3 2017 2017-10-24 B+ maintainedacceleratingexpanding 7/9 2/9
Q2 2017 2017-07-25 A raisedacceleratingexpanding 8/9 1/9
Q1 2017 2017-04-30 A raisedacceleratingexpanding 8/9 1/9
Q4 2016 2017-01-31 B maintainedstablestable 7/9 2/9
Q3 2016 2016-10-21 A maintainedstableexpanding 8/9 1/9
Q2 2016 2016-07-26 A raisedacceleratingexpanding 8/9 1/9
Q1 2016 2016-04-26 A raisedstableexpanding 8/9 2/9
Q4 2015 2016-01-26 B maintainedmixedcontracting 8/9 3/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of PCH's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

A Q1 2018 earnings call 2018-05-04

1 more research questions answered NO

B+ Q3 2017 earnings call 2017-10-24

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAXN · Axon Enterprise'sACIC · American Coastal InsuranACSAF · ACS, Actividades de ConsACU · Acme United CorporationADC · Agree Realty CorporationADPT · Adaptive Biotechnologies

PCG   All “P” companies    PCLN

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.